medigraphic.com
ISSN 0188-2198 (Impreso)

2004, Número 1

<< Anterior Siguiente >>

Rev Mex Cardiol 2004; 15 (1)


Regulación normal de la presión arterial sistémica

Cruz MA, León HFJ, Hernández y HH

Idioma: Español
Referencias bibliográficas: 82
Paginas: 30-41
Archivo PDF: 123.05 Kb.


RESUMEN

La ecuación que establece que la presión arterial resulta de multiplicar el gasto cardiaco por las resistencias periféricas totales, se antoja muy simple; sin embargo, es extremadamente compleja de aplicar desde el punto de vista biológico, están involucrados una serie grande de mecanismos biológicos, variados en su origen y en su interacción. Con el fin de estudiarlos y lograr una buena comprensión del lector, se han dividido considerando la rapidez y duración de su efecto en: Mecanismos rápidos. Son aquellos que actúan en segundos, entre los que están los nerviosos y los químicos. Mecanismos intermedios. El inicio de su efecto lo tenemos en minutos, es el grupo más numeroso y está representado por los humorales y los físicos. Mecanismos lentos. Son los de inicio más lento, pero de mayor duración, y está representado por la función del riñón y los líquidos corporales.



REFERENCIAS (EN ESTE ARTÍCULO)

  1. Swales JD. Regulation of blood pressure and hypertension. Oxford: Blackwell Science. 1995.

  2. Swales JD. Genetics of hypertension. Oxford: Blackwell Science, 1995

  3. Guyton AC. The overall system for arterial pressure regulation. In: Textbook of Medical Physiology. Philadelphia; Saunders 1991: 268.

  4. Guyton AC. Nervous regulation of the circulation, and rapid control of arterial pressure. In: Textbook of Medical Physiology. Philadelphia; Saunders 1991: 194-204

  5. Nobak CR, Demorest RJ. Cranial nerves. In: The Nervous System. New York: McGraw-Hill; 1986: 180-181

  6. Guyton AC. The reflex mechanisms for maintaining normal arterial pressure. In: Textbook of Medical Physiology. Philadelphia: Saunders 1991: 201

  7. Ferrario CM. Central nervous System mechanisms of blood pressure control in normotensive and hypertensive states. Chest 1983; 83(2): 306-308. Supplement

  8. Ahlquist RP. A study of the adrenotopic receptors. Am J Physiol 1948; 153: 586-600.

  9. Berthelsen S, Pettinger WA. A functional basis for classifications of alfa-adrenergic receptors. Life Sci 1977; 21: 696-706.

  10. Berthelsen S, Pettinger WA. A functional basis for classifications of alfa-adrenergic receptors. Life Sci 1977; 21: 595-606.

  11. Langer SZ. Presynaptic receptors and their role in the regulation of transmitter release. Br J Pharmacol 1977; 60: 481-498.

  12. Gross F. Central alfa-adrenoceptors in cardiovascular regulations. Chest 1983; 83(2): 293-296.Supplement

  13. Drew GM, Whiting SB. Evidence for two distinct types of postsynaptic alpha adrenoceptors in vascular smoot muscle in vivo. Br J Pharmacol 1979; 67: 207-215.

  14. Wikberg JES. The pharmacological classification of adrenergic alfa-1 and alfa-2 receptors and their mechanisms of action. Acta Physiol Scand 1979; 468: 1-99. Supplement

  15. Pichler L. Involvement of presynaptic and postsynaptic alfa-adrenoceptors in the action of clonidine-like substances. In: Pharmacological control of heart and circulation. Budapest: Pergamon Prees and Akadémiai Kiadó 1980; 1: 191-195.

  16. Guyton AC. Effects of different ion and other chemical factors on vascular control. In: Textbook of Medical Physiology. Philadelphia: Saunders 1991: 192.

  17. Aronson PS, Thieir SO. El riñón. En: Fisiopatología. Principios biológicos de la enfermedad. Buenos Aires: Panamericana 1988: 613-620.

  18. Guyton AC. Dominant role of the kidney in long-term regulation of arterial pressure and in hypertension: The integrated system for pressure control. In: Textbook of Medical Physiology. Philadelphia: Saunders 1991: 205-219.

  19. Maxwell MH, Wask AU, Krishna GG. Electrolytes in the pathogenesis of hypertension. Part I. Altered sodium and potassium balance. In: Narins RG (ed). Clinical Disorders of Fluids and Electrolytes Metabolism. New York: McGraw-Hill 1994: 1591-1599.

  20. Tuck ML, Corry DB. Electrolytes in the pathogenesis of hypertension. Part II: Cation transport. In: Narins RG (ed). Clinical Disorders of Fluids and Electrolyte Metabolism. New York: McGraw-Hill 1994: 1599-1608.

  21. Adragna NC. Red cell lithium-sodium countertransport and sodium-potassium cotransport in patients with essential hypertension. Hypertension 1982; 4: 795.

  22. Brugnara C. Lithium-sodium countertransport in erythrocytes of normal and hypertension subjects. Hypertension 1983; 5: 529.

  23. Burg M. Thick ascending limb of Henle’s loop. Kidney Int 1982; 22: 454.

  24. Blaustein MP. Role of natriuretic factor in essential hypertension. An hypothesis. Ann Inter Med 1983; 98: 785.

  25. Abbrecht PH. Cardiovascular effects of chronic potassium deficiency in dogs. Am J Physiol 1972: 223-555.

  26. Dluhy RG. Influence of dietary potassium on plasma rennin activity normal man. J Appl Physiol 1970; 28: 299.

  27. Resnick IM, Laragh JH, Sealey JE, Alderman MH. Divalent cations in essential hypertension: relation between serum and ionized calcium, magnesium and plasma rennin activity. N Engl J Med 1983; 309: 888-891.

  28. Zemel MB, Gualdoni SM, Sowers JR. Sodium excretion and plasma rennin activity in normotensive and hypertensive blacks adults as affected by dietary calcium and sodium. J Hypertension 1986; 4(Suppl 6): 5343-5345.

  29. Giles TD, Massie BM. Role of calcium antagonist as initial pharmacologic monotherapy for systemic hypertension in patients over 60 years of age. Am J Cardiol 1988; 61(16): 13H-17H.

  30. Quamme GA, Dirks JH. Magnesium metabolism. In: Narins RG (ed). Clinical Disorders of fluids and electrolytes metabolism. New York: McGraw-Hill 1994; 373-379.

  31. Agus ZS. Cytosolic magnesium modulates calcium channel activity in mammalian ventricular cells. Am J Physiol 1989; 256: C456.

  32. Altura BM, Altura BT. Role of magnesium in the pathogenesis of hypertension. Relationship to its actions on cardiacand muscular smoot muscle. In: Hypertension: Pathophysiology, Diagnosis, and Management. New York: raven Press 1970: 1003.

  33. Guyton AC. Intermediate mechanisms for arterial pressure regulation. In: Textbook of Medical Physiology. Philadelphia: Saunders 1991: 277.

  34. Humphreys MH, Lin SY. Peptide hormones and the regulation of sodium excretion. Hypertension 1988; 11(5): 397-410.

  35. Farías MG. Renina. En: Química Clínica. México: Manual Moderno 1988: 634.

  36. Guyton AC. Humoral regulation of the circulation. In: Textbook of Medical Physiology. Philadelphia: Saunders 1991: 191-192.

  37. Jackson EK, Garrison JC. The renin-angiotensin system. In: The Pharmacological Basis of Therapeutics. New York: McGraw-Hill 1996: 733-742.

  38. Guyton AC. The rennin-angiotensine system: Its role in pressure control and hypertension. In: Textbook of Medical Physiology. Philadelphia: Saunders 1991: 211-216.

  39. Catravas JD, Orfanos SE. Pathophysiologic functions of endotelial angiotensin-converting enzyme. In: Vascular Endothelium. New York: Schattauer 1997: 193-201.

  40. Ferrario CM, Gildenberg PL. Cardiovascular effects of angiotensine mediated by the central nervous system. Cir Res 1972; 30: 257-262.

  41. Ferrario CM, Dickinson CJ, Mc Cubbin JW. Central vasomotor stimulation by angiotensin. Clin Sci 1970; 239: 239-245.

  42. Jackson EK. Vasopresin and other agents affecting the renal conservation of water. In: The Pharmacological Basis of Therapeutics. New York: McGraw-Hill 1996: 715-731.

  43. Schoolwerth AC. Clinical assessment of renal function. In: Textbook of Critical Care. Philadelphia: Saunders 1995: 1023-1024.

  44. Ausiello DA. Natriuretic Hormones. In: Cecil Textbook of Medicine. Philadelphia: Saunders 1996: 1194-1196.

  45. Fifer MA, Molina CR, Quiroz AC et al. Hemodynamic and renal effects of arterial natriuretic peptide in congestive heart failure. Am J Cardiol 1990; 65: 211-215.

  46. Nagano M, Bravo EL. Impaired aldosterone production by long-term infusion of arterial natriuretic factor. Am J Physiol 1990; 21: 51-56.

  47. Serafin WE, Babe KS Jr. Bradykinin and kallidin and heir antagonists. In: The pharmacological Basis of Therapeutics. New York: McGraw-Hill 1996: 593-597.

  48. Scili AG, Farhy R, Scili G, Nolly H. The kallikrein-knin system in heart and vascular tissue. In: The Role Bradykinin in the Cardiovascular Action of Ramipril. Frankfurt: Hoechst 1991: 17-27.

  49. Nakagawa M, Nasjletti A. Plasma kinin concentration in deoxycorticosterone-salt hypertension. Hypertension 1988; 11: 411-415.

  50. Resinine T, Pasternak G. Opioid analgesics and antagonists. In: The Pharmacological Basis of Therapeutics. New York. McGraw-Hill 1996: 521-527.

  51. De Jong W, Petti MA, Sitsen JMA. Role of peptides in brain mechanisms regulating blood pressure. Chest 1983; 83(2): 263-308. Suppl.

  52. Gile TD, Sander GE. Interactions of leucine-encephalin with alfa-adrenoceptors in the conscious dog. Chest 1983; 83(2):363-366. Suppl.

  53. Campell WB, Halushka PV. Lipid Derived Autocoids. Eicosanoids and Platelet-Activiting Factor. In: The Pharmacological Basis of Therapeutics. New York: McGraw-Hill 1996: 601-611.

  54. Chang J, Mausser JH, McGregor H. Phospholipasa A2: function and pharmacological regulation. Biochem Pharmacol 1987; 36: 2429-2436.

  55. O’Flaherty JT. Phospholipid metabolism and stimuls-response coupling. Biochem Pharmacol 1987; 36: 407-412.

  56. Vadas P, Pruznanski W. Role of secretory phospholipasa A2 in the pathobiology of disease. Lav Invest 1986; 55: 391-399.

  57. Rubin LJ, Groves BM, Reeves JT et al. Prostacyciclin-induced acute pulmonary vasodilatation in primary pulmonary hypertension. Circulation 1982; 66(2): 334-338.

  58. Miurhead EE. The renomedullary system of blood pressure control. Am J Med Sci 295; 4: 231-233.

  59. Schimmer BP, Parker KL. Adrenocorticall Steroids. In: The Pharmacological Basis of Therapeutics. New York: McGraw-Hill 1996: 1465-1470.

  60. Guyton AC. Functions of the mineralcorticoids-aldosterone. In: Textbook of Medical Physiology. Philadelphia: Saunders 1991: 843-846.

  61. Salem M, Guarino AH, Chernow B. Regulation of mineralcorticoide release and actions. In: The Textbook of Critical Care. Philadelphia: Saunders 1995: 1094-1095.

  62. Hulter HN. Adrenal steroid hormones. In: Clinical Disorders of fluids and electrolytes metabolism. New York-Mc Graw-Hill 1994: 399-431.

  63. Bebe KS, Serafin WE. Histamine. In: The pharmacological Basis of Therapeutics. New York: McGraw-Hill 1996: 581-586.

  64. Sanders BE, Mayer SE. 5-Hydrocitryptamine (Serotonin) Receptor Agonists and Antagonists. In: The Pharmacological Basis of the Therapeutics. New York: McGraw-Hill 1996: 249-263.

  65. Oates JA. Carcinoid Syndrome. In: Cecil Textbook of Medicine. Philadelphia: Saunders 1996: 1348-1350.

  66. Loscalzo J. Nitric oxide. In: Principles of Internal Medicine. New York McGraw-Hill 1998: 442-444.

  67. Ignarro LJ. Physiologic and Pathophysiologic Significance of Mutric Oxide. In: The Textbook of Critical Care. Philadelphia: Saunders 1995: 208-215.

  68. Wylam ME. Nitric Oxide. In: Pulmonary and clinical Care Pharmacology and Therapeutics. New York: McGraw-Hill 1996: 218-220.

  69. Synder SH, Bredt DS. Biological roles if nitric oxide. Sci Am 1992; 266: 68-77.

  70. Münzel T, Just H, Harrison DG. The physiology and pathophysiology of the nitric oxide/superoxide system. In: Vascular Endothelium. Physiology. Pathology and Therapeutic Opportunities. Stuttgart: Schattauer 1197: 205-217.

  71. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288(5789): 373.

  72. Haddad IY, Pitt BR, Matalon S. Nitric oxide in lung injury. In: Sishman’s Pulmonary Diseased and Disorders. New York; Mc-GrawHill 1998: 337-346.

  73. Sütsch G, Wensel R, Kiowski W, Lüscher T. Endothelium and its role in vascular physiology/biology. In: Vascular Endothelium Physiology, pathology and Therapeutic Opportunities. Stuttgart: Schattauer 1997: 221-242.

  74. Schiffrin EL. Endothelium: role in hypertension. In: Vascular Endothelium. Physiology, Pathology and Therapeutic Opportunities. Stuttgart: Schattauer 1997: 355-372.

  75. Mylam ME. Endothelium. In: Pulmonary and Clinical Care Pharmacology and Therapeutics. New York: McGraw-Hill 1996: 214-216.

  76. Yanagisawa M, Kurihara H, Kimui S, Tomobe Y, Kobayashi M, Mitsui Y, Yzaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produce by vascular endothelial cells. Nature 1989; 332: 411-415.

  77. Lüscher TF, Wenzel RR, Noll G. Local regulation of the coronary circulation in the health and disease: role of nitric oxide and endothelin. Eur Hear J 1995; 16: C15-58.

  78. Guyton AC. Formation of urine by the kidney: I: Renal blood Flow, glomerular filtration and their control. In: Textbook of Medical Physiology. Philadelphia: Saunders 1991: 286-297.

  79. Saxenhofer H, Roselli A, Weidmann et al. Urodilatin a natriuretic factor from kidneys, can modify renal and cardiovascular function in men. Am J Physiol 1990; 259: F832-838.

  80. Jackson EK. Renal anatomy and physiology. In: The Pharmacological Basis of Therapeutics. New York: McGraw-Hill 1996: 685-690.

  81. Scholwerth AC, Gher TWB. Renal boold flow. In: Textbook of Critical Care. Philadelphia: Saunders 1995: 1018-1020.

  82. Teitelbaum I, Kleeman CR, Berl T. The physiology of the renal concentrating and diluting mechanisms. In: Clinical Disorders of Fluid and Electrolyte Metabolism. New York: McGraw-Hill 1994: 101-111.




2020     |     www.medigraphic.com